{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:02:41Z","timestamp":1776384161959,"version":"3.51.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postgraduate Innovation Research and Practice Program of Anhui Medical University"},{"name":"Research Foundation of Anhui Medical University"},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation of Anhui Institute of Translational Medicine"},{"name":"Health Research Program of Anhui"},{"DOI":"10.13039\/501100017668","name":"Key Research and development Project of Anhui Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04747-1","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:28:39Z","timestamp":1773145719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated multi-target pharmacology of ginseng in acute myeloid leukemia through single-cell sequencing, molecular docking, network pharmacology, and in vitro experiments"],"prefix":"10.1007","volume":"17","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-qing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"10","key":"4747_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 2024;10(10):1417\u201325.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4747_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Huang G, Cai X, et al. Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024;12(1):101.","journal-title":"Biomark Res"},{"issue":"11","key":"4747_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s11864-022-01021-8","volume":"23","author":"S Chakraborty","year":"2022","unstructured":"Chakraborty S, Park CY. Pathogenic mechanisms in acute myeloid leukemia. Curr Treat Options Oncol. 2022;23(11):1522\u201334.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"4747_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11\u201320.","journal-title":"Blood"},{"issue":"3","key":"4747_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"key":"4747_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv B, Wang Y, Ma D, et al. Immunotherapy: reshape the Tumor Immune Microenvironment. Front Immunol. 2022;13:844142.","journal-title":"Front Immunol"},{"key":"4747_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.","journal-title":"Pharmacol Res"},{"key":"4747_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","volume":"39","author":"X Ren","year":"2021","unstructured":"Ren X, Zhang L, Zhang Y, et al. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol. 2021;39:583\u2013609.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"4747_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/JLB.4RI0818-311R","volume":"106","author":"CE Olingy","year":"2019","unstructured":"Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309\u201322.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"4747_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","volume":"43","author":"H Song","year":"2025","unstructured":"Song H, Chen L, Pan X, et al. Targeting tumor monocyte-intrinsic PD-L1 by rewiring signaling and enhancing STING agonist therapy. Cancer Cell. 2025;43(3):503-518.e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"4747_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100776","volume":"8","author":"B Fendl","year":"2023","unstructured":"Fendl B, Berghoff AS, Preusser M, et al. Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy. ESMO Open. 2023;8(1):100776.","journal-title":"ESMO Open"},{"issue":"1","key":"4747_CR12","doi-asserted-by":"publisher","first-page":"19811","DOI":"10.1038\/s41598-024-65345-1","volume":"14","author":"P Miao","year":"2024","unstructured":"Miao P, Yu J, Chen Z, et al. Establishment and verification of a TME prognosis scoring model based on the acute myeloid leukemia single-cell transcriptome. Sci Rep. 2024;14(1):19811.","journal-title":"Sci Rep"},{"issue":"3","key":"4747_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41375-020-0932-8","volume":"35","author":"M Cerrano","year":"2021","unstructured":"Cerrano M, Duchmann M, Kim R, et al. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia. 2021;35(3):712\u201323.","journal-title":"Leukemia"},{"issue":"3","key":"4747_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"4747_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood.2023021680","volume":"144","author":"F Mazziotta","year":"2024","unstructured":"Mazziotta F, Biavati L, Rimando J, et al. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024;144(11):1168\u201382.","journal-title":"Blood"},{"issue":"26","key":"4747_CR16","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu J, Rutella S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia. Blood. 2024;143(26):2689\u2013700.","journal-title":"Blood"},{"key":"4747_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12935-020-01468-5","volume":"20","author":"ZY Nie","year":"2020","unstructured":"Nie ZY, Zhao MH, Cheng BQ, et al. Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p\/AKT3 axis. Cancer Cell Int. 2020;20:379.","journal-title":"Cancer Cell Int"},{"key":"4747_CR18","doi-asserted-by":"publisher","first-page":"1388903","DOI":"10.3389\/fphar.2024.1388903","volume":"15","author":"X Gao","year":"2024","unstructured":"Gao X, Zuo X, Min T, et al. Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets. Front Pharmacol. 2024;15:1388903.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4747_CR19","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/molecules28093863","volume":"28","author":"JA Vald\u00e9s-Gonz\u00e1lez","year":"2023","unstructured":"Vald\u00e9s-Gonz\u00e1lez JA, S\u00e1nchez M, Moratilla-Rivera I, et al. Immunomodulatory, anti-inflammatory, and anti-cancer properties of ginseng: a pharmacological update. Molecules. 2023;28(9):3863.","journal-title":"Molecules"},{"issue":"24","key":"4747_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24244501","volume":"24","author":"W Chen","year":"2019","unstructured":"Chen W, Balan P, Popovich DG. Review of ginseng anti-diabetic studies. Molecules. 2019;24(24):4501.","journal-title":"Molecules"},{"issue":"4","key":"4747_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang J, Liu D, Wang Y, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of anti-PD-1\/PD-L1 immunotherapy. Gut. 2022;71(4):734\u201345.","journal-title":"Gut"},{"key":"4747_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117049","volume":"177","author":"Y Yang","year":"2024","unstructured":"Yang Y, Nan Y, Du Y, et al. Ginsenosides in cancer: proliferation, metastasis, and drug resistance. Biomed Pharmacother. 2024;177:117049.","journal-title":"Biomed Pharmacother"},{"key":"4747_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115037","volume":"165","author":"SJ Hwang","year":"2023","unstructured":"Hwang SJ, Bang HJ, Lee HJ. Ginsenoside Re inhibits melanogenesis and melanoma growth by downregulating microphthalmia-associated transcription factor. Biomed Pharmacother. 2023;165:115037.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4747_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12951-023-02006-x","volume":"21","author":"J Kim","year":"2023","unstructured":"Kim J, Zhu Y, Chen S, et al. Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood-brain-barrier penetration and tumor microenvironment modulation. J Nanobiotechnology. 2023;21(1):253.","journal-title":"J Nanobiotechnology"},{"key":"4747_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110812","volume":"132","author":"W Qi","year":"2020","unstructured":"Qi W, Yan X, Xu X, et al. The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells. Biomed Pharmacother. 2020;132:110812.","journal-title":"Biomed Pharmacother"},{"key":"4747_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"4747_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01105-2","volume":"14","author":"Y Lei","year":"2021","unstructured":"Lei Y, Tang R, Xu J, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14(1):91.","journal-title":"J Hematol Oncol"},{"key":"4747_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107066","volume":"161","author":"S Guo","year":"2023","unstructured":"Guo S, Liu X, Zhang J, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer. Comput Biol Med. 2023;161:107066.","journal-title":"Comput Biol Med"},{"issue":"8","key":"4747_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"4747_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116306","volume":"309","author":"L Zhao","year":"2023","unstructured":"Zhao L, Zhang H, Li N, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J Ethnopharmacol. 2023;309:116306.","journal-title":"J Ethnopharmacol"},{"issue":"9","key":"4747_CR31","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1681\/ASN.0000000698","volume":"36","author":"SS Xie","year":"2025","unstructured":"Xie SS, Hou R, Gao L, et al. Insulin-like growth factor-binding protein 7 and cadmium-induced hepatorenal fibrosis. J Am Soc Nephrol. 2025;36(9):1716\u201332.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4747_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep. 2024;26(4):409\u201320.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"4747_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/carcin\/bgs341","volume":"34","author":"KS Chung","year":"2013","unstructured":"Chung KS, Cho SH, Shin JS, et al. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-\u03b2 expression. Carcinogenesis. 2013;34(2):331\u201340.","journal-title":"Carcinogenesis"},{"issue":"8","key":"4747_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.273","volume":"4","author":"AD Kim","year":"2013","unstructured":"Kim AD, Kang KA, Kim HS, et al. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis. 2013;4(8):e750.","journal-title":"Cell Death Dis"},{"key":"4747_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104727","volume":"155","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li MY, Zhang ZH, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727.","journal-title":"Pharmacol Res"},{"key":"4747_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105392","volume":"116","author":"L Xu","year":"2021","unstructured":"Xu L, Zhang X, Xiao S, et al. Panaxadiol as a major metabolite of AD-1 can significantly inhibit the proliferation and migration of breast cancer cells: in vitro and in vivo study. Bioorg Chem. 2021;116:105392.","journal-title":"Bioorg Chem"},{"issue":"37","key":"4747_CR37","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1021\/acs.jafc.2c04298","volume":"70","author":"L Xu","year":"2022","unstructured":"Xu L, Xiao S, Lee JJ, et al. In vivo metabolites of panaxadiol inhibit HepG-2 cell proliferation by inducing G1 arrest and ROS-mediated apoptosis. J Agric Food Chem. 2022;70(37):11560\u201371.","journal-title":"J Agric Food Chem"},{"issue":"4","key":"4747_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"9","key":"4747_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113127","volume":"42","author":"S Abe","year":"2023","unstructured":"Abe S, Asahi T, Hara T, et al. Hematopoietic cell-derived IL-15 supports NK cell development in scattered and clustered localization within the bone marrow. Cell Rep. 2023;42(9):113127.","journal-title":"Cell Rep"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04747-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:16:52Z","timestamp":1776381412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04747-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4747"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04747-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"578"}}